Polycythemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}}; {{AE}}{{SSH}}
{{CMG}}; {{AE}}{{SSH}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Polycythemia]]
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Polycythemia]]
==Overview==
==Overview==
Polycythemia manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary and secondary polycythemia must be differentiated from each other. Primary polycythemia might be seen in patients with various [[Mutation|mutations]]. [[Iatrogenic]] causes including [[medications]], athletic drugs, and [[smoking]] might cause primary polycythemia. Secondary polycythemia must be differentiated in patients with chronic [[hypoxemia]], [[erythropoietin]] producing [[Tumor|tumors]], or [[Arteriovenous malformation|arteriovenous malformations]].   
[[Polycythemia]] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary and secondary [[polycythemia]] must be differentiated from each other. Primary [[polycythemia]] might be seen in patients with various [[Mutation|mutations]]. [[Iatrogenic]] causes including [[medications]], athletic drugs, and [[smoking]] might cause primary [[polycythemia]]. Secondary [[polycythemia]] must be differentiated in patients with chronic [[hypoxemia]], [[erythropoietin]] producing [[Tumor|tumors]], or [[Arteriovenous malformation|arteriovenous malformations]].   


==Differential Diagnosis of Polycythemia==
==Differential Diagnosis of Polycythemia==
Line 44: Line 45:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mutational causes
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mutational causes
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]] (PV)<ref name="SteinOh2015">{{cite journal|last1=Stein|first1=Brady L.|last2=Oh|first2=Stephen T.|last3=Berenzon|first3=Dmitriy|last4=Hobbs|first4=Gabriela S.|last5=Kremyanskaya|first5=Marina|last6=Rampal|first6=Raajit K.|last7=Abboud|first7=Camille N.|last8=Adler|first8=Kenneth|last9=Heaney|first9=Mark L.|last10=Jabbour|first10=Elias J.|last11=Komrokji|first11=Rami S.|last12=Moliterno|first12=Alison R.|last13=Ritchie|first13=Ellen K.|last14=Rice|first14=Lawrence|last15=Mascarenhas|first15=John|last16=Hoffman|first16=Ronald|title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F|journal=Journal of Clinical Oncology|volume=33|issue=33|year=2015|pages=3953–3960|issn=0732-183X|doi=10.1200/JCO.2015.61.6474}}</ref>
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]] (PV)<ref name="SteinOh2015">{{cite journal|last1=Stein|first1=Brady L.|last2=Oh|first2=Stephen T.|last3=Berenzon|first3=Dmitriy|last4=Hobbs|first4=Gabriela S.|last5=Kremyanskaya|first5=Marina|last6=Rampal|first6=Raajit K.|last7=Abboud|first7=Camille N.|last8=Adler|first8=Kenneth|last9=Heaney|first9=Mark L.|last10=Jabbour|first10=Elias J.|last11=Komrokji|first11=Rami S.|last12=Moliterno|first12=Alison R.|last13=Ritchie|first13=Ellen K.|last14=Rice|first14=Lawrence|last15=Mascarenhas|first15=John|last16=Hoffman|first16=Ronald|title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F|journal=Journal of Clinical Oncology|volume=33|issue=33|year=2015|pages=3953–3960|issn=0732-183X|doi=10.1200/JCO.2015.61.6474}}</ref>
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Autonomous [[erythrocyte]] production
*Autonomous [[erythrocyte]] production
| align="center" style="background:#F5F5F5;" |[[JAK2]] mutation (> 95%)
| align="center" style="background:#F5F5F5;" |[[JAK2]] mutation (> 95%)
| align="center" style="background:#F5F5F5;" | Mean age >60 years old
| align="center" style="background:#F5F5F5;" |Mean age >60 years old
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Erythromelagia]]
*[[Erythromelagia]]
* [[Chest pain]]
*[[Chest pain]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Stroke]]-like symptoms
*[[Stroke]]-like symptoms
* [[Pruritis]]
*[[Pruritis]]
* [[Dizziness]]
*[[Dizziness]]
* [[Visual disturbance]]
*[[Visual disturbance]]
| align="center" style="background:#F5F5F5;" |Facial plethora
| align="center" style="background:#F5F5F5;" |Facial [[plethora]]
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Painful [[erythema]]
*Painful [[erythema]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑ RBC mass
| align="center" style="background:#F5F5F5;" |↑ RBC mass
Line 76: Line 77:
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↓
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Elevated normochromic, normocytic [[Red blood cell|RBCs]]
*Elevated normochromic, normocytic [[Red blood cell|RBCs]]
* [[Thrombocytosis]]  
*[[Thrombocytosis]]
* Rarely immature cells  
*Rarely immature cells
* Leukoerythroblastic picture
*Leukoerythroblastic picture
| align="center" style="background:#F5F5F5;" |WHO criteria for PV
| align="center" style="background:#F5F5F5;" |WHO criteria for PV
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Stroke]]
*[[Stroke]]
* [[Venous thrombosis]]
*[[Venous thrombosis]]
* [[Myelofibrosis]]
*[[Myelofibrosis]]
* [[Acute leukemia]]
*[[Acute leukemia]]
|-
|-
! align="center" style="background:#DCDCDC;" |Chuvash polycythemia<ref name="ZhouKnoche2016">{{cite journal|last1=Zhou|first1=Amy W.|last2=Knoche|first2=Eric M.|last3=Engle|first3=Elizabeth K.|last4=Ban-Hoefen|first4=Makiko|last5=Kaiwar|first5=Charu|last6=Oh|first6=Stephen T.|title=Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia|journal=New England Journal of Medicine|volume=375|issue=5|year=2016|pages=494–496|issn=0028-4793|doi=10.1056/NEJMc1600337}}</ref>
! align="center" style="background:#DCDCDC;" |Chuvash polycythemia<ref name="ZhouKnoche2016">{{cite journal|last1=Zhou|first1=Amy W.|last2=Knoche|first2=Eric M.|last3=Engle|first3=Elizabeth K.|last4=Ban-Hoefen|first4=Makiko|last5=Kaiwar|first5=Charu|last6=Oh|first6=Stephen T.|title=Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia|journal=New England Journal of Medicine|volume=375|issue=5|year=2016|pages=494–496|issn=0028-4793|doi=10.1056/NEJMc1600337}}</ref>
| align="center" style="background:#F5F5F5;" | Hypoxia-sensing disorder
| align="center" style="background:#F5F5F5;" |Hypoxia-sensing disorder
| align="center" style="background:#F5F5F5;" | [[VHL gene|VHL]] mutation
| align="center" style="background:#F5F5F5;" |[[VHL gene|VHL]] mutation
| align="center" style="background:#F5F5F5;" | Russia, Italy
| align="center" style="background:#F5F5F5;" |Russia, Italy
<40 years old
<40 years old
| align="center" style="background:#F5F5F5;" |  +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ±
| align="left" style="background:#F5F5F5;" |
* [[Arthralgia]]
| align="left" style="background:#F5F5F5;" |
* [[Pruritis]]
* [[Dizziness]]
| align="center" style="background:#F5F5F5;" | Facial plethora
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | ↑
| align="left" style="background:#F5F5F5;" |
* Painful [[erythema]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |±
* [[Lymphadenopathy]]
| align="left" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | ↑
*[[Arthralgia]]
| align="center" style="background:#F5F5F5;" | ↑
| align="left" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Nl
*[[Pruritis]]
| align="center" style="background:#F5F5F5;" | Nl
*[[Dizziness]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |Facial plethora
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |↓
* Elevated normochromic, normocytic [[Red blood cell|RBCs]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Molecular [[genetic testing]]
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Multiple [[thrombotic events]]
*Painful [[erythema]]
| align="center" style="background:#F5F5F5;" | +
| align="left" style="background:#F5F5F5;" |
*[[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
*Elevated normochromic, normocytic [[Red blood cell|RBCs]]
| align="center" style="background:#F5F5F5;" |Molecular [[genetic testing]]
| align="left" style="background:#F5F5F5;" |
*Multiple [[thrombotic events]]
|-
|-
! align="center" style="background:#DCDCDC;" |Hereditary [[methemoglobinemia]]<ref name="pmid12897322">{{cite journal |vauthors=Da-Silva SS, Sajan IS, Underwood JP |title=Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report |journal=Pediatrics |volume=112 |issue=2 |pages=e158–61 |date=August 2003 |pmid=12897322 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |Hereditary [[methemoglobinemia]]<ref name="pmid12897322">{{cite journal |vauthors=Da-Silva SS, Sajan IS, Underwood JP |title=Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report |journal=Pediatrics |volume=112 |issue=2 |pages=e158–61 |date=August 2003 |pmid=12897322 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* [[Cytochrome b5 reductase]] deficiency
*[[Cytochrome b5 reductase]] deficiency
* Hemoglobin M disease
*Hemoglobin M disease
| align="center" style="background:#F5F5F5;" | [[Mutations]] in [[Globin|globin gene]]
| align="center" style="background:#F5F5F5;" |[[Mutations]] in [[Globin|globin gene]]
| align="center" style="background:#F5F5F5;" | Infants
| align="center" style="background:#F5F5F5;" |Infants
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | [[Cyanosis]]
| align="center" style="background:#F5F5F5;" |[[Cyanosis]]
| align="center" style="background:#F5F5F5;" | Inaccurately Nl
| align="center" style="background:#F5F5F5;" |Inaccurately Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* [[Altered mental status]]
*[[Altered mental status]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" | RBC enzyme activity + [[DNA]] analysis  
| align="center" style="background:#F5F5F5;" |RBC enzyme activity + [[DNA]] analysis
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Usually asymptomatic
*Usually asymptomatic
|-
|-
! align="center" style="background:#DCDCDC;" |Primary familial and congenital polycythemia<ref>Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/</ref>
! align="center" style="background:#DCDCDC;" |Primary familial and congenital polycythemia<ref>Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/</ref>
| align="center" style="background:#F5F5F5;" | [[Autosomal dominant]] inheritance
| align="center" style="background:#F5F5F5;" |[[Autosomal dominant]] inheritance
| align="center" style="background:#F5F5F5;" | EPOR mutation
| align="center" style="background:#F5F5F5;" |EPOR mutation
| align="center" style="background:#F5F5F5;" | Very rare
| align="center" style="background:#F5F5F5;" |Very rare
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Facial plethora
| align="center" style="background:#F5F5F5;" |Facial plethora
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
*[[Altered mental status]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" | Nl to ↑
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Isolated [[erythrocytosis]] + [[genetic testing]]
| align="center" style="background:#F5F5F5;" | −
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
*Mild manifestations of hyperviscosity
* [[Altered mental status]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" | Isolated [[erythrocytosis]] + [[genetic testing]]
| align="left" style="background:#F5F5F5;" |  
* Mild manifestations of hyperviscosity
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
Line 209: Line 210:
! align="center" style="background:#DCDCDC;" |[[Smoking]]<ref name="Hasselbalch2015">{{cite journal|last1=Hasselbalch|first1=Hans Carl|title=Smoking as a contributing factor for development of polycythemia vera and related neoplasms|journal=Leukemia Research|volume=39|issue=11|year=2015|pages=1137–1145|issn=01452126|doi=10.1016/j.leukres.2015.09.002}}</ref><ref name="MalenicaPrnjavorac2017">{{cite journal|last1=Malenica|first1=Maja|last2=Prnjavorac|first2=Besim|last3=Bego|first3=Tamer|last4=Dujic|first4=Tanja|last5=Semiz|first5=Sabina|last6=Skrbo|first6=Selma|last7=Gusic|first7=Amar|last8=Hadzic|first8=Ajla|last9=Causevic|first9=Adlija|title=Effect of Cigarette Smoking on Haematological Parameters in Healthy Population|journal=Medical Archives|volume=71|issue=2|year=2017|pages=132|issn=0350-199X|doi=10.5455/medarh.2017.71.132-136}}</ref>
! align="center" style="background:#DCDCDC;" |[[Smoking]]<ref name="Hasselbalch2015">{{cite journal|last1=Hasselbalch|first1=Hans Carl|title=Smoking as a contributing factor for development of polycythemia vera and related neoplasms|journal=Leukemia Research|volume=39|issue=11|year=2015|pages=1137–1145|issn=01452126|doi=10.1016/j.leukres.2015.09.002}}</ref><ref name="MalenicaPrnjavorac2017">{{cite journal|last1=Malenica|first1=Maja|last2=Prnjavorac|first2=Besim|last3=Bego|first3=Tamer|last4=Dujic|first4=Tanja|last5=Semiz|first5=Sabina|last6=Skrbo|first6=Selma|last7=Gusic|first7=Amar|last8=Hadzic|first8=Ajla|last9=Causevic|first9=Adlija|title=Effect of Cigarette Smoking on Haematological Parameters in Healthy Population|journal=Medical Archives|volume=71|issue=2|year=2017|pages=132|issn=0350-199X|doi=10.5455/medarh.2017.71.132-136}}</ref>


| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Reduced plasma volume
*Reduced plasma volume
* Accelerated [[erythropoiesis]]
*Accelerated [[erythropoiesis]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | [[Cyanosis]]
| align="center" style="background:#F5F5F5;" |[[Cyanosis]]
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl to ↑
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" | Nl to ↑
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" | Clinical manifestation
| align="center" style="background:#F5F5F5;" |Clinical manifestation
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |NA
|-
|-
! align="center" style="background:#DCDCDC;" |[[Carbon monoxide poisoning|Chronic exposure to carbon monoxide]]<ref name="WuJuurlink2014">{{cite journal|last1=Wu|first1=P. E.|last2=Juurlink|first2=D. N.|title=Carbon monoxide poisoning|journal=Canadian Medical Association Journal|volume=186|issue=8|year=2014|pages=611–611|issn=0820-3946|doi=10.1503/cmaj.130972}}</ref>
! align="center" style="background:#DCDCDC;" |[[Carbon monoxide poisoning|Chronic exposure to carbon monoxide]]<ref name="WuJuurlink2014">{{cite journal|last1=Wu|first1=P. E.|last2=Juurlink|first2=D. N.|title=Carbon monoxide poisoning|journal=Canadian Medical Association Journal|volume=186|issue=8|year=2014|pages=611–611|issn=0820-3946|doi=10.1503/cmaj.130972}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Occupational exposure
*Occupational exposure
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Miners, fire fighters
| align="center" style="background:#F5F5F5;" |Miners, fire fighters
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* [[Dizziness]]
*[[Dizziness]]
* [[Altered mental state|Altered cognition]]
*[[Altered mental state|Altered cognition]]
| align="center" style="background:#F5F5F5;" | [[Cyanosis]], flushed cheeks
| align="center" style="background:#F5F5F5;" |[[Cyanosis]], flushed cheeks
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" | Blood level of [[carboxyhemoglobin]]
| align="center" style="background:#F5F5F5;" |Blood level of [[carboxyhemoglobin]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Concomitant [[cyanide]] exposure
*Concomitant [[cyanide]] exposure
|-
|-
! align="center" style="background:#DCDCDC;" |[[Diuretic|Diuretics]]<ref name="pmid3282731">{{cite journal |vauthors=Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF |title=Erythrocythemia following renal transplantation: influence of diuretic therapy |journal=Clin. Nephrol. |volume=29 |issue=3 |pages=119–23 |date=March 1988 |pmid=3282731 |doi= |url=}}</ref>  
! align="center" style="background:#DCDCDC;" |[[Diuretic|Diuretics]]<ref name="pmid3282731">{{cite journal |vauthors=Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF |title=Erythrocythemia following renal transplantation: influence of diuretic therapy |journal=Clin. Nephrol. |volume=29 |issue=3 |pages=119–23 |date=March 1988 |pmid=3282731 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Reduced plasma volume
*Reduced plasma volume
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Dizziness]]
*[[Dizziness]]
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Clinical manifestation
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | NA
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |Clinical manifestation
| align="center" style="background:#F5F5F5;" |NA
|-
|-
! align="center" style="background:#DCDCDC;" |Use of [[Androgen|androgens]] or [[Anabolic steroid|anabolic steroids]]<ref name="pmid1942342">{{cite journal |vauthors=Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM |title=Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence |journal=J. Urol. |volume=146 |issue=6 |pages=1566–70 |date=December 1991 |pmid=1942342 |doi= |url=}}</ref><ref name="pmid9072584">{{cite journal |vauthors=Morales A, Johnston B, Heaton JP, Lundie M |title=Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes |journal=J. Urol. |volume=157 |issue=3 |pages=849–54 |date=March 1997 |pmid=9072584 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |Use of [[Androgen|androgens]] or [[Anabolic steroid|anabolic steroids]]<ref name="pmid1942342">{{cite journal |vauthors=Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM |title=Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence |journal=J. Urol. |volume=146 |issue=6 |pages=1566–70 |date=December 1991 |pmid=1942342 |doi= |url=}}</ref><ref name="pmid9072584">{{cite journal |vauthors=Morales A, Johnston B, Heaton JP, Lundie M |title=Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes |journal=J. Urol. |volume=157 |issue=3 |pages=849–54 |date=March 1997 |pmid=9072584 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Reduced plasma volume
*Reduced plasma volume
* Accelerated [[erythropoiesis]]
*Accelerated [[erythropoiesis]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Athletes
| align="center" style="background:#F5F5F5;" |Athletes
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | [[Acne vulgaris|Acne]] and [[hirsutism]]
| align="center" style="background:#F5F5F5;" |[[Acne vulgaris|Acne]] and [[hirsutism]]
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Gynecomastia]]  
*[[Gynecomastia]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" | Clinical manifestation
| align="center" style="background:#F5F5F5;" |Clinical manifestation
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hypogonadism]]  
*[[Hypogonadism]]
* [[Cardiomegaly|Cardiac hypertrophy]]  
*[[Cardiomegaly|Cardiac hypertrophy]]
|-
|-
! align="center" style="background:#DCDCDC;" |Self−injection of [[erythropoietin]]<ref name="Elliott20082">{{cite journal|last1=Elliott|first1=S|title=Erythropoiesis-stimulating agents and other methods to enhance oxygen transport|journal=British Journal of Pharmacology|volume=154|issue=3|year=2008|pages=529–541|issn=00071188|doi=10.1038/bjp.2008.89}}</ref>
! align="center" style="background:#DCDCDC;" |Self−injection of [[erythropoietin]]<ref name="Elliott20082">{{cite journal|last1=Elliott|first1=S|title=Erythropoiesis-stimulating agents and other methods to enhance oxygen transport|journal=British Journal of Pharmacology|volume=154|issue=3|year=2008|pages=529–541|issn=00071188|doi=10.1038/bjp.2008.89}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
* Reduced plasma volume
*Reduced [[plasma]] volume
* Accelerated [[erythropoiesis]]
*Accelerated [[erythropoiesis]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Athletes
| align="center" style="background:#F5F5F5;" |Athletes
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Muscular body
| align="center" style="background:#F5F5F5;" |Muscular body
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |[[Erythropoietin]] level
| align="center" style="background:#F5F5F5;" |[[Erythropoietin]] level
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[ST elevation myocardial infarction|MI]]  
*[[ST elevation myocardial infarction|MI]]
* [[Stroke]]  
*[[Stroke]]
* [[Thrombosis|Thromboembolic disease]]  
*[[Thrombosis|Thromboembolic disease]]
* Antibody-mediated anemia  
*Antibody-mediated anemia
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Secondary causes
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Secondary causes
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[hypoxemia]]<ref name="NadeemGui2012">{{cite journal|last1=Nadeem|first1=Omar|last2=Gui|first2=Jiang|last3=Ornstein|first3=Deborah L.|title=Prevalence of Venous Thromboembolism in Patients With Secondary Polycythemia|journal=Clinical and Applied Thrombosis/Hemostasis|volume=19|issue=4|year=2012|pages=363–366|issn=1076-0296|doi=10.1177/1076029612460425}}</ref>
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[hypoxemia]]<ref name="NadeemGui2012">{{cite journal|last1=Nadeem|first1=Omar|last2=Gui|first2=Jiang|last3=Ornstein|first3=Deborah L.|title=Prevalence of Venous Thromboembolism in Patients With Secondary Polycythemia|journal=Clinical and Applied Thrombosis/Hemostasis|volume=19|issue=4|year=2012|pages=363–366|issn=1076-0296|doi=10.1177/1076029612460425}}</ref>
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Chronic obstructive pulmonary disease|Chronic lung disease]]
*[[Chronic obstructive pulmonary disease|Chronic lung disease]]
* [[Right-to-left shunt|Right-to-left cardiac shunts]]
*[[Right-to-left shunt|Right-to-left cardiac shunts]]
* [[Sleep apnea]]
*[[Sleep apnea]]
* [[Altitude sickness|High altitude]]
*[[Altitude sickness|High altitude]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Shortness of breath]]
*[[Shortness of breath]]
| align="center" style="background:#F5F5F5;" |[[Cyanosis]]
| align="center" style="background:#F5F5F5;" |[[Cyanosis]]
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↓
Line 380: Line 381:
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Crackles]]
*[[Crackles]]
* [[Tachypnea]]
*[[Tachypnea]]
* [[Tachycardia]]
*[[Tachycardia]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
Line 391: Line 392:
| align="center" style="background:#F5F5F5;" |Clinical manifestation + imaging
| align="center" style="background:#F5F5F5;" |Clinical manifestation + imaging
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Variable manifestations given the diverse etiologies
*Variable manifestations given the diverse etiologies
|-
|-
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[erythropoietin]] producing tumor<ref name="pmid2297568">{{cite journal |vauthors=Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P, Varet B |title=Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia |journal=Blood |volume=75 |issue=3 |pages=577–82 |date=February 1990 |pmid=2297568 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[erythropoietin]] producing tumor<ref name="pmid2297568">{{cite journal |vauthors=Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P, Varet B |title=Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia |journal=Blood |volume=75 |issue=3 |pages=577–82 |date=February 1990 |pmid=2297568 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |
*[[Renal cell carcinoma]]
*[[Renal cell carcinoma]]
*[[Hepatocellular carcinoma]]
*[[Hepatocellular carcinoma]]
*Cerebellar [[hemangioblastoma]]
*[[Cerebellar]] [[hemangioblastoma]]
*[[Pheochromocytoma]]
*[[Pheochromocytoma]]
*[[Leiomyoma|Uterine fibroids]]
*[[Leiomyoma|Uterine fibroids]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" |Depends on etiology
| align="center" style="background:#F5F5F5;" |Chronically ill
| align="center" style="background:#F5F5F5;" |Chronically ill
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | Nl to ↑
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |±
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hepatomegaly]]
*[[Hepatomegaly]]
* [[Bruising]]
*[[Bruising]]
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |↑/↓
Line 425: Line 426:
| align="center" style="background:#F5F5F5;" |Clinical manifestation + [[biopsy]]
| align="center" style="background:#F5F5F5;" |Clinical manifestation + [[biopsy]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Variable manifestations given the diverse etiologies
*Variable manifestations given the diverse etiologies
|-
|-
! align="center" style="background:#DCDCDC;" |[[Hereditary hemorrhagic telangiectasia]]<ref>McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1351/</ref>
! align="center" style="background:#DCDCDC;" |[[Hereditary hemorrhagic telangiectasia]]<ref>McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1351/</ref>
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pulmonary arteriovenous malformation|Pulmonary arteriovenous malformations]]
*[[Pulmonary arteriovenous malformation|Pulmonary arteriovenous malformations]]
| align="center" style="background:#F5F5F5;" |ACVRL1, ENG, GDF2, SMAD4 mutation
| align="center" style="background:#F5F5F5;" |[[ACVRL1]], [[ENG]], [[GDF2]], [[SMAD4]] mutation
| align="center" style="background:#F5F5F5;" |Children
| align="center" style="background:#F5F5F5;" |Children
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | [[Gastrointestinal bleeding|GI bleeding]]
| align="center" style="background:#F5F5F5;" |[[Gastrointestinal bleeding|GI bleeding]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Epistaxis]]
*[[Epistaxis]]
* [[Hemoptysis]]
*[[Hemoptysis]]
| align="center" style="background:#F5F5F5;" |Multiple [[telangiectasia]] on face, extremities, and body
| align="center" style="background:#F5F5F5;" |Multiple [[telangiectasia]] on face, extremities, and body
| align="center" style="background:#F5F5F5;" | Nl to ↓
| align="center" style="background:#F5F5F5;" |Nl to ↓
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | ↑/↓
| align="center" style="background:#F5F5F5;" | ↑/↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | ↑/↓
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑/↓
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |Clinical criteria + genomic testing
| align="center" style="background:#F5F5F5;" |Clinical criteria + genomic testing
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Dominance relationship|Autosomal dominant]]
*[[Dominance relationship|Autosomal dominant]]
* [[Pulmonary hypertension]]
*[[Pulmonary hypertension]]
* [[Cerebral arteriovenous malformation|Cerebral AVMs]]
*[[Cerebral arteriovenous malformation|Cerebral AVMs]]
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category

Latest revision as of 16:16, 2 March 2021


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Polycythemia manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary and secondary polycythemia must be differentiated from each other. Primary polycythemia might be seen in patients with various mutations. Iatrogenic causes including medications, athletic drugs, and smoking might cause primary polycythemia. Secondary polycythemia must be differentiated in patients with chronic hypoxemia, erythropoietin producing tumors, or arteriovenous malformations.

Differential Diagnosis of Polycythemia

Polycythemia must be differentiated from a variety of other conditions.[1][2][3]

Category Disease Etiology Mutation Clinical manifestations Laboratory findings Gold standard disgnosis Associated findings
Demography Symptoms Signs CBC EPO level PBS
Fatigue Headache Shortness of breath Bleeding Pain Other symptoms Appearance SaO2 Fever BP Tenderness Splenomegaly Other signs Hb RBC WBC Plt
Mutational causes Polycythemia vera (PV)[4] JAK2 mutation (> 95%) Mean age >60 years old + + + ± Facial plethora Nl + ↑ RBC mass Nl to ↑ Nl to ↑
  • Elevated normochromic, normocytic RBCs
  • Thrombocytosis
  • Rarely immature cells
  • Leukoerythroblastic picture
WHO criteria for PV
Chuvash polycythemia[5] Hypoxia-sensing disorder VHL mutation Russia, Italy

<40 years old

+ + + ± Facial plethora + Nl Nl
  • Elevated normochromic, normocytic RBCs
Molecular genetic testing
Hereditary methemoglobinemia[6] Mutations in globin gene Infants ± ± ± Cyanosis Inaccurately Nl Nl Nl Nl Nl NA RBC enzyme activity + DNA analysis
  • Usually asymptomatic
Primary familial and congenital polycythemia[7] Autosomal dominant inheritance EPOR mutation Very rare + + ± Facial plethora Nl Nl to ↑ Nl Nl Nl to ↓ NA Isolated erythrocytosis + genetic testing
  • Mild manifestations of hyperviscosity
Category Disease Etiology Mutation Demography Fatigue Headache Shortness of breath Bleeding Pain Other symptoms Appearance SaO2 Fever BP Tenderness Splenomegaly Other signs Hb RBC WBC Plt EPO level PBS Gold standard diagnosis Associated findings
Iatrogenic causes Smoking[8][9] Any + Cyanosis Nl Nl Nl to ↑ Nl to ↑ Nl to ↓ NA Clinical manifestation NA
Chronic exposure to carbon monoxide[10]
  • Occupational exposure
Miners, fire fighters + + + Cyanosis, flushed cheeks Nl Nl Nl Nl Nl to ↓ NA Blood level of carboxyhemoglobin
Diuretics[11]
  • Reduced plasma volume
Any Nl Nl Nl to ↓ Nl Nl Nl Nl to ↓ NA Clinical manifestation NA
Use of androgens or anabolic steroids[12][13] Athletes + + Acne and hirsutism Nl Nl to ↑ Nl Nl NA Clinical manifestation
Self−injection of erythropoietin[14] Athletes + + Muscular body Nl Nl NA Erythropoietin level
Secondary causes Secondary polycythemia due to hypoxemia[15] Depends on etiology + + + Depends on etiology Cyanosis Nl to ↑ Nl Nl NA Clinical manifestation + imaging
  • Variable manifestations given the diverse etiologies
Secondary polycythemia due to erythropoietin producing tumor[16] Depends on etiology + Depends on etiology Depends on etiology Chronically ill Nl ± Nl to ↑ ± ± ↑/↓ ↑/↓ Nl NA Clinical manifestation + biopsy
  • Variable manifestations given the diverse etiologies
Hereditary hemorrhagic telangiectasia[17] ACVRL1, ENG, GDF2, SMAD4 mutation Children + + GI bleeding Multiple telangiectasia on face, extremities, and body Nl to ↓ Nl ↑/↓ ↑/↓ Nl Nl ↑/↓ NA Clinical criteria + genomic testing
Category Disease Etiology Mutation Demography Fatigue Headache Shortness of breath Bleeding Pain Other symptoms Appearance SaO2 Fever BP Tenderness Splenomegaly Other signs Hb RBC WBC Plt EPO level PBS Gold standard diagnosis Associated findings

References

  1. Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
  2. Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
  3. Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.
  4. Stein, Brady L.; Oh, Stephen T.; Berenzon, Dmitriy; Hobbs, Gabriela S.; Kremyanskaya, Marina; Rampal, Raajit K.; Abboud, Camille N.; Adler, Kenneth; Heaney, Mark L.; Jabbour, Elias J.; Komrokji, Rami S.; Moliterno, Alison R.; Ritchie, Ellen K.; Rice, Lawrence; Mascarenhas, John; Hoffman, Ronald (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F". Journal of Clinical Oncology. 33 (33): 3953–3960. doi:10.1200/JCO.2015.61.6474. ISSN 0732-183X.
  5. Zhou, Amy W.; Knoche, Eric M.; Engle, Elizabeth K.; Ban-Hoefen, Makiko; Kaiwar, Charu; Oh, Stephen T. (2016). "Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia". New England Journal of Medicine. 375 (5): 494–496. doi:10.1056/NEJMc1600337. ISSN 0028-4793.
  6. Da-Silva SS, Sajan IS, Underwood JP (August 2003). "Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report". Pediatrics. 112 (2): e158–61. PMID 12897322.
  7. Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/
  8. Hasselbalch, Hans Carl (2015). "Smoking as a contributing factor for development of polycythemia vera and related neoplasms". Leukemia Research. 39 (11): 1137–1145. doi:10.1016/j.leukres.2015.09.002. ISSN 0145-2126.
  9. Malenica, Maja; Prnjavorac, Besim; Bego, Tamer; Dujic, Tanja; Semiz, Sabina; Skrbo, Selma; Gusic, Amar; Hadzic, Ajla; Causevic, Adlija (2017). "Effect of Cigarette Smoking on Haematological Parameters in Healthy Population". Medical Archives. 71 (2): 132. doi:10.5455/medarh.2017.71.132-136. ISSN 0350-199X.
  10. Wu, P. E.; Juurlink, D. N. (2014). "Carbon monoxide poisoning". Canadian Medical Association Journal. 186 (8): 611–611. doi:10.1503/cmaj.130972. ISSN 0820-3946.
  11. Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF (March 1988). "Erythrocythemia following renal transplantation: influence of diuretic therapy". Clin. Nephrol. 29 (3): 119–23. PMID 3282731.
  12. Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM (December 1991). "Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence". J. Urol. 146 (6): 1566–70. PMID 1942342.
  13. Morales A, Johnston B, Heaton JP, Lundie M (March 1997). "Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes". J. Urol. 157 (3): 849–54. PMID 9072584.
  14. Elliott, S (2008). "Erythropoiesis-stimulating agents and other methods to enhance oxygen transport". British Journal of Pharmacology. 154 (3): 529–541. doi:10.1038/bjp.2008.89. ISSN 0007-1188.
  15. Nadeem, Omar; Gui, Jiang; Ornstein, Deborah L. (2012). "Prevalence of Venous Thromboembolism in Patients With Secondary Polycythemia". Clinical and Applied Thrombosis/Hemostasis. 19 (4): 363–366. doi:10.1177/1076029612460425. ISSN 1076-0296.
  16. Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P, Varet B (February 1990). "Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia". Blood. 75 (3): 577–82. PMID 2297568.
  17. McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1351/